NASDAQ$LAB
Standard Biotool · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported third quarter results with core product and services revenue increasing sequentially and restructuring program improving operating margin.
Standard BioTools announced its third quarter 2022 financial results, highlighting a sequential increase in core product and services revenue and improvements in operating margin due to restructuring efforts. The company is focused on commercial execution, operational efficiency, and expense reduction.
- Core product and service revenue increased 30% sequentially to $24.8 million.
- First phase of restructuring program improved operating margin by 600 to 800 basis points on an annualized basis.
- Reiterated goal of 700 to 1000 basis point non-GAAP product and service gross margin improvement to 65-68% by year end 2023.
- On track to achieve positive free cash flow by year-end 2024.
Headline financials
Revenue & EPS history
Standard Biotool · Revenue · Quarterly
$25.6M
Forward guidance
Standard BioTools is focused on achieving its financial and operational goals through commercial execution, operational efficiency, and expense reduction. The company is targeting improved margins and positive free cash flow.
Tailwinds
- Achieving stated goal of 700 to 1000 basis point non-GAAP product and service gross margin improvement to 65-68% by year end 2023
- Focused on returning core business to growth
- Driving toward profitability
- Improving operating discipline leveraging our Standard BioTools™ Business Systems approach
- Well positioned to capitalize on current market conditions
Headwinds
- GAAP net loss for the quarter ended September 30, 2022, was $29.4 million
- The year-over-year increase in GAAP net loss was primarily due to $6.2 million of lower non-operating income and $6.1 million of business improvement charges
- Non-GAAP net loss was $20.8 million for the quarter
- Total revenue was lower instrument and COVID-19 testing revenue
- Cash, cash equivalents, and short-term investments decreased from $211.2 million as of June 30, 2022 to $185.2 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-2.7%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.6%
Avg return
30 days after
42%
19 / 45 earnings
Positive
+44.5%
Q3 2015
Best reaction
-51.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | +1.0% | +16.3% | |
| Q4 2025 | +2.6% | -4.3% | -21.7% | |
| Q3 2025 | -2.6% | +0.0% | +26.1% | |
| Q1 2025 | -3.9% | +9.4% | +0.0% | |
| Q4 2024 | -10.3% | -9.4% | -2.6% | |
| Q3 2024 | +12.0% | +5.7% | -13.7% | |
| Q2 2024 | -38.8% | -31.5% | -8.2% | |
| Q1 2024 | +1.7% | +4.6% | -2.1% | |
| Q4 2023 | -3.8% | +10.3% | +15.8% | |
| Q3 2023 | -6.9% | +6.9% | +15.2% | |
| Q2 2023 | +6.7% | +20.0% | +20.8% | |
| Q1 2023 | +9.1% | +7.3% | +33.9% | |
| Q4 2022 | +0.0% | -0.5% | +3.3% | |
| Q3 2022 | -7.9% | +32.7% | +29.7% | |
| Q2 2022 | -11.1% | -6.9% | -22.8% | |
| Q1 2022 | -5.8% | -21.4% | -37.1% | |
| Q4 2021 | +3.1% | -1.4% | +8.0% | |
| Q3 2021 | -5.1% | +0.8% | -8.2% | |
| Q2 2021 | -7.0% | -0.7% | +4.7% | |
| Q1 2021 | +5.1% | +12.5% | +12.1% | |
| Q4 2020 | -19.8% | -20.5% | -35.2% | |
| Q3 2020 | +13.5% | -18.2% | -7.7% | |
| Q2 2020 | +2.6% | +0.1% | -17.3% | |
| Q1 2020 | +15.9% | +31.9% | +0.0% | |
| Q4 2019 | -0.3% | -3.7% | -30.6% | |
| Q3 2019 | -51.0% | -54.5% | -51.0% | |
| Q2 2019 | -31.5% | -40.0% | -52.5% | |
| Q1 2019 | -10.4% | -13.2% | -1.4% | |
| Q4 2018 | +10.4% | +17.5% | +37.4% | |
| Q3 2018 | +2.1% | +1.7% | +13.9% | |
| Q2 2018 | +7.0% | +8.4% | +26.1% | |
| Q1 2018 | -2.2% | -7.1% | -5.3% | |
| Q4 2017 | +13.4% | +30.3% | +17.8% | |
| Q3 2017 | +1.8% | -7.4% | +4.7% | |
| Q2 2017 | -3.1% | -4.9% | +44.9% | |
| Q1 2017 | +17.3% | +16.1% | -3.6% | |
| Q4 2016 | -1.6% | +0.3% | -18.1% | |
| Q3 2016 | -1.8% | +11.1% | +48.8% | |
| Q2 2016 | -12.2% | -13.4% | -15.8% | |
| Q1 2016 | +5.4% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +44.5% | — | — | |
| Q2 2015 | -35.8% | — | — | |
| Q1 2015 | -26.4% | — | — | |
| Q4 2014 | +2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro